Press release 1 Ipsen delivers excellent H1 2026 results and upgrades its full-year guidance • H1 2026 results with sales growth of 23.5% at CER 1 , or 20.4% as reported, with the portfolio beyond Somatuline® achieving sales growth of 24.8% 1 and…
Press release
1
Ipsen delivers excellent H1 2026 results and upgrades
its full-year guidance
• H1 2026 results with sales growth of 23.5% at CER
1
, or 20.4% as reported, with the portfolio beyond
Somatuline® achieving sales growth of 24.8%
1
and core operating income of €845m, growing by 28.8%
as reported, with a core operating margin of 38.6% of total sales, increasing by 2.5 points
• Upgraded FY 2026 financial guidance
2
: total sales growth greater than 20.0% at CER (prior guidance:
greater than 13.0% at CER); core operating margin greater than 37.0% of total sales (prior guidance:
greater than 35.0%)
• Delivering on strategy to accelerate the growth of key medicines and expand the pipeline, adding
multiple anticipated near-term launches of assets with blockbuster potential across the three
therapeutic areas. Driven by several positive Phase III readouts, for Dysport® in episodic and chronic
migraine, Iqirvo® in primary biliary cholangitis and the acquisitions of Kartos Therapeutics
3
and Memo
Therapeutics AG
PARIS, FRANCE, 30 July 2026 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care
biopharmaceutical company, today presents its financial results for the first half of 2026.
“Our excellent first-half performance demonstrates the strength of Ipsen’s strategy, with all three
therapeutic areas contributing to growth and the portfolio beyond Somatuline continuing to accelerate,”
said David Loew, Chief Executive Officer, Ipsen. “This momentum enables us to upgrade our 2026
guidance while continuing to invest in innovation and future growth. Importantly, we have significantly
strengthened our late-stage pipeline in the first half, with positive Phase III lifecycle management readouts
for Dysport in episodic and chronic migraine and Iqirvo in primary biliary cholangitis, alongside the
completed acquisition of Memo Therapeutics AG and the proposed acquisition of Kartos Therapeutics.
These transactions add two innovative clinical assets—navtemadlin and potravitug—with the potential to
address significant unmet needs and create long-term value. Our expanding pipeline and focused
business development strategy further contribute to Ipsen’s sustainable growth outlook and our ability
to bring meaningful innovation to patients worldwide.”
1
At constant exchange rates (CER), which exclude any foreign-exchange impact by recalculating the performance for the relevant period by applying the exchange rates
used for the prior period.
2
Excluding any impact from potential late-stage (Phase III clinical development or later) external-innovation transactions.
3
Subject to satisfaction of customary deal closing conditions
Extract of consolidated results
H1 2026 H1 2025 % change
€m €m Actual
CER
Total Sales 2,190.2 1,819.8 20.4 % 23.5 %
Core Operating Income 844.9 655.8 28.8 %
Core operating margin 38.6 % 36.0 % +2.5 pts
Core Consolidated Net Profit 607.7 508.3 19.6 %
Core earnings per share (fully diluted) €7.33 €6.07 20.7 %
IFRS Operating Income 564.8 451.6 25.1 %
IFRS operating margin 25.8 % 24.8 % +1.0 pts
IFRS Consolidated Net Profit 402.6 335.5 20.0 %
IFRS earnings per share (fully diluted) €4.86 €4.00 21.4 %
Free Cash Flow 651.7 483.2 34.9 %
Closing net cash/(debt) 1,004.9 487.6 n/a
Press release
2
Full-year 2026 guidance
Based on the strong performance in the first half, Ipsen upgrades its financial guidance for 2026:
• Total sales growth greater than 20.0%, at constant currency. Based on the average level of exchange
rates in June 2026, an adverse effect on total sales of around 1% of currencies is expected
• Core operating margin greater than 37.0% of total sales, which includes additional R&D expenses from
anticipated early and mid-stage external innovation opportunities and assumes the dilutive impact of
the acquisitions of Memo Therapeutics AG and Kartos Therapeutics
Guidance
4
on total sales and core operating margin in 2026 is assuming accelerated sales growth of the
portfolio excluding Somatuline and the continued growth of Somatuline sales despite potential entry of
generic lanreotide.
Pipeline progress since Q1 2026
Ipsen presented in May late-breaking Phase II data in Glabellar Lines for corabotase, its first-in-class
recombinant neuroinhibitor (RNI™), demonstrating a rapid onset of action, a statistically superior peak
effect versus placebo at Week 4 and a clinically significant sustained duration of effect, outperforming
both placebo and Dysport at Week 24. Corabotase has been recognized by the WHO (World Health
Organization) and USAN (United States Adopted Name) as a novel botase molecule.
Ipsen announced positive topline Phase III results from the BEOND migraine program in July, with Dysport
meeting the primary endpoint in both the episodic, E-BEOND and chronic, C-BEOND trials by
demonstrating statistically significant reductions in monthly migraine days versus placebo. These results
make Dysport the first botulinum toxin to show efficacy in Phase III trials across both episodic and chronic
migraine prevention. Dysport was well tolerated, with a safety profile consistent with its established use
and no new safety signals identified. Ipsen intends to submit to regulatory authorities and detailed results
will be presented at a future scientific congress.
Ipsen announced positive topline results from the Phase IIIb ELSPIRE study of Iqirvo in primary biliary
cholangitis (PBC) in July. The study met its primary endpoint, with 85% of patients receiving Iqirvo
achieving alkaline phosphatase (ALP) normalization at Week 52 versus 23% on placebo (p=<0.0001), while
maintaining a safety profile consistent with previous studies and identifying no new safety signals.
ELSPIRE evaluated patients with ALP levels of 1-1.67x ULN, and supports the potential to significantly
expand the addressable population for Iqirvo. Ipsen plans to submit the data to regulatory authorities
and present these data at an upcoming scientific congress.
Ipsen announced in July that the Phase III BOLD trial evaluating Bylvay® (odevixibat) versus placebo in
patients with biliary atresia who had already undergone a Kasai hepatoportoenterostomy did not meet
its primary endpoint of improved native liver survival. Topline safety data remained consistent with
odevixibat's well-established profile in its approved indications, with no new signals identified.
External innovation
Ipsen recently announced its agreement to acquire Kartos Therapeutics, a clinical-stage
biopharmaceutical company, centered on navtemadlin, a Phase III oral MDM2 inhibitor for myelofibrosis
designed to restore p53 tumor-suppressor activity in patients with a suboptimal response to ruxolitinib.
Top-line data from the registrational POIESIS trial are expected in 2027. Under the terms of the
agreement, Kartos shareholders will receive $450m upfront and may be eligible for up to $1.3bn in
milestone payments, with closing anticipated by the end of Q3 2026, subject to customary conditions.
Ipsen acquired Memo Therapeutics AG in July, a clinical-stage biotechnology company focused on
potravitug, a Phase II antibody targeting BK polyomavirus (BKPyV), a frequent cause of nephropathy, graft
4
Excluding any impact from potential late-stage (Phase III clinical development or later) external-innovation transactions.
Press release
3
loss and transplant failure in kidney transplant recipients. Potravitug received FDA Fast Track designation
in 2023 and EU Orphan Drug designation in 2025. Under the terms of the agreement, Memo Therapeutics
AG shareholders received €200m upfront, with the potential for total consideration exceeding €700m
through development, regulatory and sales milestones.
Consolidated financial statements
The Board of Directors approved the condensed consolidated financial statements on 29 July 2026. The
Company’s auditors performed a limited review of the H1 2026 condensed consolidated financial
statements. The interim financial report, with regards to the regulated information, will be available on
ipsen.com in due course, under the Reports and Accounts tab in the Investor Relations section.
Conference call
A conference call and webcast for investors and analysts will begin today at 2pm CEST. Participants can
access the webcast here. Analysts can join the call and ask questions by registering here.
Calendar
Ipsen intends to publish its year-to-date and third-quarter sales update on 22 October 2026.
Notes
All financial figures are in € millions (€m). The performance shown in this announcement covers the six-
month period to 30 June 2026 (H1 2026) and the three-month period to 30 June 2026 (Q2 2026),
compared to the six-month period to 30 June 2025 (H1 2025) and the three-month period to 30 June
2025 (Q2 2025), respectively, unless stated otherwise. Commentary is based on the performance in H1
2026, unless stated otherwise.
About Ipsen
We are a global biopharmaceutical company with a focus on bringing transformative medicines to
patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by
internal and external innovation and supported by nearly 100 years of development experience and
global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships
around the world enable us to bring medicines to patients in more than 100 countries.
Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary
Receipt program (ADR: IPSEY). For more information, visit ipsen.com.
Ipsen Contacts
Investors
Henry Wheeler [email protected] – +33 7 64 47 11 49
Khalid Deojee [email protected] – +33 6 66 01 95 26
Media
Sally Bain [email protected] – +1 857 320 05 17
Anne Liontas [email protected] – +33 7 67 34 72 96
Press release
4
Total sales by therapy area and medicine
H1
2026
H1
2025
% change
Q2
2026
Q2
2025
% change
€m €m Actual CER
€m €m Actual CER
Oncology
1,451.5 1,288.0 12.7 % 15.6 %
744.0 633.0 17.5 % 18.2 %
Somatuline
®
686.3 588.6 16.6 % 21.0 %
357.5 278.2 28.5 % 29.7 %
Cabometyx
®
350.5 296.7 18.1 % 18.8 %
181.4 149.9 21.1 % 21.1 %
Decapeptyl
®
284.3 277.1 2.6 % 3.5 %
140.2 141.3 -0.8 % -1.1 %
Onivyde
®
108.0 102.7 5.2 % 11.2 %
54.9 51.0 7.7 % 10.0 %
Ojemda
®
14.5 0.9 n/a n/a
9.2 0.5 n/a n/a
Other Oncology
7.9 22.0 -63.9 % -61.8 %
0.7 12.1 -93.9 % -94.1 %
Rare Disease
304.7 153.4 98.6 % 108.0 %
157.6 83.1 89.7 % 94.0 %
Iqirvo
®
173.2 58.8 194.6 % 209.7 %
94.4 35.5 165.9 % 174.1 %
Bylvay
®5
120.1 86.6 38.6 % 44.8 %
58.9 43.2 36.3 % 38.4 %
Other Rare Disease
11.4 8.0 42.7 % 47.2 %
4.3 4.4 -1.4 % -0.8 %
Neuroscience
434.0 378.4 14.7 % 16.6 %
213.7 184.9 15.6 % 14.7 %
Dysport
®
427.1 371.0 15.1 % 17.2 %
210.1 180.7 16.3 % 15.5 %
Dysport Aesthetics
256.8 221.4 16.0 % 19.6 %
119.5 104.3 14.5 % 14.6 %
Dysport Therapeutics
170.2 149.5 13.8 % 13.8 %
90.6 76.3 18.7 % 16.9 %
Other Neuroscience
6.9 7.5 -7.1 % -12.9 %
3.6 4.2 -14.8 % -20.1 %
Total Sales
2,190.2 1,819.8 20.4 % 23.5 %
1,115.3 901.0 23.8 % 24.5 %
• Somatuline: strong sales growth reflecting generic lanreotide challenges in North America and Europe,
in addition to a solid performance in Rest of World.
• Cabometyx: strong sales growth with solid volume performance in Europe and in Rest of World, with
growing contribution from the neuroendocrine tumor indication launches, mainly in Germany.
• Decapeptyl: sales growth driven by solid demand and favorable shipment phasing in Rest of World,
despite lower performance in Europe due to competition and pricing pressure. Q2 negative
performance due to Rest of World adverse shipment phasing comparison after a strong shipment base
in the first quarter.
• Onivyde: sales growth driven by the U.S. and higher sales to ex-U.S. partner.
• Ojemda: first sales, mainly related to specialized access schemes in Rest of World and launch in
Germany.
• Other Oncology: including impact of the voluntary Tazverik withdrawal in March 2026.
• Iqirvo: accelerated sales growth in the U.S. and additional launches across European countries.
• Bylvay: strong growth in both indications in the U.S., Europe, and some Rest of World countries.
• Other Rare Disease: including Sohonos sales growth driven by increased number of new patients.
• Dysport: sales growth driven by both aesthetics and therapeutics indications across all geographies,
despite flat aesthetic sales in North America due to unfavorable phasing of shipments.
5
Including sales of odevixibat under the brand name Kayfanda® approved in European Union for cholestatic pruritus in Alagille Syndrome
Press release
5
Total sales by geographical area
H1
2026
H1
2025
% change
Q2
2026
Q2
2025
% change
€m €m Actual CER €m €m Actual CER
North America
795.4 634.9 25.3 % 34.0 %
404.5 300.7 34.5 % 38.1 %
Europe
6
824.1 721.9 14.1 % 14.2 %
416.5 364.5 14.3 % 14.3 %
Rest of World
570.7 463.0 23.3 % 24.2 %
294.3 235.8 24.8 % 22.7 %
Total Sales
2,190.2 1,819.8 20.4 % 23.5 %
1,115.3 901.0 23.8 % 24.5 %
North America: strong double-digit sales growth driven by the increased contribution of Iqirvo and Bylvay
in Rare Disease, as well as Somatuline benefiting from generic lanreotide challenges, despite limited
growth of Dysport in aesthetics impacted by unfavorable phasing of orders.
Europe: double-digit sales growth driven by Cabometyx and Somatuline benefiting from generic
lanreotide challenges, the increased contribution of Iqirvo and Bylvay in Rare Disease, as well as solid
performance of Dysport.
Rest of World: strong double-digit sales growth driven by the solid performance of Dysport aesthetics and
Decapeptyl, the continued growth of Cabometyx, and the increased contribution of Iqirvo and Bylvay in
Rare Disease.
6
Defined in this announcement as the E.U., the U.K., Iceland, Liechtenstein, Norway and Switzerland
Press release
6
Core consolidated income statement
The consolidated income statement includes a reclassification of the distribution expenses, previously
recorded in Selling general and administrative expenses to the Cost of sales to provide a more relevant
presentation of the performance indicators. As a consequence, 2025 figures have been adjusted
proforma to reflect this change. The distribution expenses amounted to €44m in H1 2026 and €46m in
H1 2025 (see Appendix 1.2).
H1 2026 H1 2025
% change
€m % of sales €m % of sales
Total Sales 2,190.2 100.0 % 1,819.8 100.0 % 20.4 %
Other revenues 109.0 5.0 % 117.3 6.4 % (7.0) %
Cost of sales (435.2) (19.9) % (371.0) (20.4) % 17.3 %
Gross Margin 1,864.0 85.1 % 1,566.1 86.1 % 19.0 %
Selling general and administrative expenses (607.7) (27.7) % (560.7) (30.8) % 8.4 %
Research and development expenses (402.5) (18.4) % (364.9) (20.1) % 10.3 %
Other core income and expenses (9.0) (0.4) % 15.3 0.8 % (158.7) %
Core Operating Income 844.9 38.6 % 655.8 36.0 % 28.8 %
Net financing costs (3.3) (0.2) % (4.2) (0.2) % (21.0) %
Core other financial income and expense (16.0) (0.7) % (6.5) (0.4) % 147.1 %
Core income taxes (217.9) (9.9) % (136.9) (7.5) % 59.1 %
Core consolidated Net Profit 607.7 27.7 % 508.3 27.9 % 19.6 %
- Attributable to shareholders of Ipsen S.A. 608.2 27.8 % 506.8 27.8 % 20.0 %
- Attributable to non-controlling interests (0.5) — % 1.5 0.1 % n/a
Core EPS fully diluted - attributable to Ipsen
S.A. shareholders (in € per share)
7
€7.33
€6.07
20.7 %
Total sales
Total sales in H1 grew by 20.4% as reported, to €2,190.2m, including an adverse impact from currencies
of 3.1%.
Other revenues
Other revenues totaled €109.0m, a decrease of 7.0%, mainly due to higher commercial and regulatory
milestones received from Ipsen partners in H1 2025, despite the growth in royalties received primarily
from Dysport partner.
Cost of sales
Cost of sales of €435.2m (including distribution expenses) represented 19.9% of total sales, an
improvement of 0.5 percentage point (H1 2025: €371.0m, or 20.4%), reflecting a favorable product mix.
Selling, general, and administrative expenses
Selling, general, and administrative expenses of €607.7m (excluding distribution expenses) increased by
8.4%, driven by the investment in commercial efforts to support launches, partly offset by the impact of
the efficiency program. Selling, general, and administrative expenses amounted to 27.7% of total sales,
7
Earnings per share
Press release
7
an improvement of 3.1 percentage points (H1 2025: €560.7m, or 30.8%).
Research and development expenses
Research and development expenses totaled €402.5m, representing a growth of 10.3%, primarily driven
by increased investment in the pipeline including corabotase in aesthetics and therapeutics, and the
recent oncology early-stage assets. Research and development expenses represented 18.4% of total
sales, a decrease of 1.7 percentage points (H1 2025: €364.9m, or 20.1%).
Other core operating income and expenses
Other core operating income and expenses amounted to an expense of €9.0m (H1 2025: €15.3m
income), reflecting the impact of exchange rate evolution and the Group hedging policy.
Core operating income
Core operating income amounted to €844.9m representing an increase of 28.8%, with a core operating
margin at 38.6% of total sales, an increase of 2.5 percentage points (H1 2025: €655.8m, or 36.0%).
Net financing costs and core other financial income and expense
The Group incurred net financial costs of €3.3m, versus €4.2m in H1 2025, with higher income on
available cash partly offset by higher interest expenses following the €500m rated public bond issued in
March 2025.
Other financial expenses increased by €9.5m, mainly from unfavorable foreign-exchange impacts on non
commercial transactions.
Core income taxes
Core income tax expense of €217.9m reflected higher income before tax, with a core effective tax rate
of 26.4% (H1 2025: 21.2%).
Core consolidated net profit
Core consolidated net profit grew by 19.6% to €607.7m (H1 2025: €508.3m).
Core Earnings per Share (EPS)
Fully diluted Core EPS at €7.33, a growth of 20.7% in line with core consolidated net profit growth (2025:
€6.07).
Press release
8
From core consolidated Net Profit to IFRS Consolidated Net Profit
H1 2026 H1 2025
€m €m
Core consolidated net profit 607.7 508.3
Amortization of intangible assets (excluding software) (92.1) (99.1)
Other operating income and expenses (41.1) (12.2)
Restructuring costs (4.1) (2.0)
Impairment losses (63.6) (39.3)
Others (4.2) (20.1)
IFRS consolidated net profit 402.6 335.5
IFRS EPS Fully diluted - attributable to Ipsen S.A. shareholders (in € per
share)
€4.86 €4.00
Amortization of intangible assets (excluding software)
Amortization of intangible assets (excluding software) amounted to €92.1m, compared to €99.1m in H1
2025 driven by the impairment losses on Tazverik in 2026 and Sohonos in 2025.
Other operating income and expenses
Other non-core operating expenses amounted to €41.1m, mainly related to Tazverik withdrawal impacts,
as compared to €12.2m in H1 2025, mainly related to discontinuation of some clinical trials.
Restructuring costs
Restructuring costs came to €4.1m (H1 2025 at €2.0m).
Impairment losses
The Group recognized an impairment loss of €63.6m mainly on the intangible value of Tazverik following
the product withdrawal in March 2026, as compared to an impairment loss of €39.3m in H1 2025 related
to discontinued preclinical R&D trials in Oncology.
Others
Other financial expenses and income taxes amounted to an expense of €4.2m compared to an expense
of €20.1m in H1 2025.
IFRS Consolidated net profit
Consolidated net profit was €402.6m (H1 2025: €335.5m), increasing by 20.0%, driven by operating
income growth of 28.8%.
Earnings per Share (EPS)
Fully diluted EPS amounted to €4.86 (H1 2025: €4.00) growing by 21.4% in line with the consolidated net
profit growth.
Press release
9
Net cash flow and financing
The Group had a closing net cash of €1,004.9m, an increase of €445.0m during the first semester of 2026
versus closing position at the end of FY 2025.
H1 2026 H1 2025
€m €m
Opening Net Cash/(Debt) 559.9 160.3
Core Operating Income 844.9 655.8
Amortization & Depreciation 45.6 43.4
EBITDA 890.4 699.2
Non-cash items 22.1 17.6
Change in operating working capital requirements (6.9) (35.6)
(Increase)/decrease in other working capital requirements (27.9) 4.5
Net capital expenditures (excluding milestones paid)
(42.7) (63.9)
Operating Cash Flow 835.0 621.8
Other non-core operating income and expenses and restructuring costs (40.8) (22.2)
Financial income (17.4) (16.8)
Tax paid (125.1) (99.6)
Free Cash Flow 651.7 483.2
Distributions paid by Ipsen S.A. (131.8) (116.2)
Net investments (Business Development, milestones and disposals) (40.1) (80.0)
Share buyback (17.3) (10.7)
FX on net indebtedness (12.0) 44.4
Other (5.6) 6.5
Shareholders return and external growth operations (206.8) (155.9)
Change in Net Cash/(Debt) 445.0 327.3
Closing Net cash/(Debt) 1,004.9 487.6
Operating cash flow
Operating cash flow totaled €835.0m, an increase of €213.2m (34.3%), driven by higher EBITDA and lower
capital expenditures.
Free cash flow
Free cash flow amounted to €651.7m, an increase of 34.9% (H1 2025: €483.2m) mainly driven by higher
operating cash flow partly offset by increase in taxes paid.
Shareholders’ return and external growth operations
The distribution payout to Ipsen S.A. shareholders amounted to €131.8m, corresponding to a dividend
per share of €1.60 (H1 2025: €116.2m, with a dividend per share of €1.40).
Net investments of €40.1m were mainly related to new business development programs and regulatory
and commercial milestones paid to the partners, partly offset by the proceeds from the sale of equity
investments shares.
Press release
10
Net investments of €80.0m in H1 2025 were mainly related to regulatory and commercial milestones
paid to the partners.
Foreign Exchange on net indebtedness negatively impacted net cash position mainly due to U.S. Dollar
versus Euro changes.
Press release
11
Reconciliation of cash and cash equivalents and net cash
H1 2026 H1 2025
€m €m
Current financial assets (derivative instruments on financial operations) 0.1 4.6
Closing cash and cash equivalents 1,961.8 1,442.9
Non-Current Loans (625.6) (745.6)
Other non-current financial liabilities (excluding derivative instruments)
8
(77.8) (92.4)
Non-current financial liabilities (703.4) (838.0)
Current Loans (131.9) —
Other current financial liabilities (excluding derivative instruments)
8
(121.7) (121.9)
Current financial liabilities (253.5) (121.9)
Debt (957.0) (959.9)
Net cash / (debt)
9
1,004.9 487.6
Analysis of Group cash
On 23 July 2019, Ipsen S.A. issued a $300m U.S. Private Placement (“USPP”) in two tranches of 7 and
10‑year maturities. Ipsen complied with its covenant ratio (net debt/EBITDA to remain below 3.5 times)
at the end of June 2026. A $150 million tranche has been repaid at maturity on 23 July 2026.
On 7 March 2025, Ipsen S.A. signed a Revolving Credit Facility (“RCF”) of €1,500m, with an initial maturity
of five years (March 2030) and two possible one-year extensions. The Group exercised one tranche in
2025, making the maturity March 2031. The revolving credit facility (RCF) was unused as of 30 June 2026.
On 25 March 2025, Ipsen S.A. issued a €500m rated public bond maturing on March 2032, based on the
Investment Grade ratings received from S&P and Moody’s.
On 30 June 2026, Ipsen S.A. also has a program of emission of NEU CP – Negotiable EUropean Commercial
Paper of €600m, from which €80m were drawn.
8
Financial liabilities mainly exclude €14.4 million in derivative instruments related to commercial operations at the end of June 2026, compared with €(19.6) million one year
earlier.
9
Net cash / (debt): including derivative instruments booked in financial assets and related to financial operations, cash and cash equivalents, less bank overdrafts, bank
loans and other financial liabilities and excluding financial derivative instruments on commercial operations
Press release
12
Appendix 1.1: consolidated income statement
H1 2026 H1 2025
€m €m
Sales 2,190.2 1,819.8
Other revenues 109.0 117.3
Cost of sales (435.2) (371.0)
Gross Margin 1,864.0 1,566.1
Selling general and administrative expenses (607.7) (560.7)
Research and development expenses (402.5) (364.9)
Other operating income and expenses (198.2) (133.1)
Restructuring costs (5.6) (2.8)
Impairment losses (85.2) (53.0)
Operating Income 564.8 451.6
Net financing costs (3.3) (4.2)
Other financial income and expenses (13.8) (21.9)
Income taxes (145.1) (89.5)
Share of net profit/(loss) from equity-accounted companies — (0.5)
Consolidated Net Profit 402.6 335.5
- Attributable to shareholders of Ipsen S.A. 403.1 334.0
- Attributable to non-controlling interests (0.5) 1.5
Basic Earnings Per Share (in euros) € 4.89 € 4.04
Diluted Earnings Per Share (in euros) € 4.86 € 4.00
Press release
13
Appendix 1.2: Distribution expenses presentation in the Core consolidated income statement
The table below presents the impact of the reclassification of the distribution expenses from Selling
general and administrative expenses to Costs of sales, with no impact on the Core Operating Income.
This reclassification aims to provide a more relevant presentation of the performance indicators. As a
consequence, H1 2025 figures have been adjusted proforma to reflect this change. The distribution
expenses amounted to €44m in H1 2026 and €46m in H1 2025.
Current Prior Change
H1 2026 H1 2025 H1 2026 H1 2025 H1 2026 H1 2025
€m €m €m €m €m €m
Total Sales 2,190.2 1,819.8 2,190.2 1,819.8 — —
Other revenues 109.0 117.3 109.0 117.3 — —
Cost of sales (435.2) (371.0) (390.8) (325.1) (44.4) (45.9)
Gross Margin 1,864.0 1,566.1 1,908.5 1,612.0 (44.4) (45.9)
% of total sales 85.1 % 86.1 % 87.1 % 88.6 % (2.0) pts (2.5) pts
Selling general and
administrative expenses
(607.7) (560.7) (652.2) (606.6) 44.4 45.9
% of total sales (27.7) % (30.8) % (29.8) % (33.3) % +2.0pts +2.5pts
Research and development
expenses
(402.5) (364.9) (402.5) (364.9) — —
% of total sales (18.4) % (20.1) % (18.4) % (20.1) % — % — %
Other core income and
expenses
(9.0) 15.3 (9.0) 15.3 — —
Core Operating Income 844.9 655.8 844.9 655.8 — —
% of total sales 38.6 % 36.0 % 38.6 % 36.0 % — % — %
Press release
14
Appendix 2: consolidated balance sheet before allocation of net profit
30 June 2026 31 December 2025
€m €m
ASSETS
Goodwill 650.4 633.8
Other intangible assets 2,116.7 2,288.2
Property, plant & equipment 661.5 668.0
Equity investments 198.5 171.3
Deferred tax assets 370.7 298.0
Other non-current assets 52.8 54.5
Total non-current assets 4,050.5 4,113.7
Inventories 201.3 240.9
Trade receivables 976.5 786.8
Current tax assets 23.3 67.2
Current financial assets 6.3 9.4
Other current assets 232.1 194.2
Cash and cash equivalents 1,970.3 1,525.5
Total current assets 3,409.8 2,824.1
TOTAL ASSETS 7,460.3 6,937.8
EQUITY AND LIABILITIES
Share capital 83.8 83.8
Additional paid-in capital and consolidated reserves 4,252.9 3,889.5
Net profit (loss) for the period 403.1 443.5
Foreign exchange differences (29.1) (80.9)
Equity attributable to Ipsen S.A. shareholders 4,710.7 4,335.9
Equity attributable to non-controlling interests 0.4 0.9
Total shareholders' equity 4,711.1 4,336.9
Retirement benefit obligation 28.2 26.0
Non-current provisions 36.2 20.9
Other non-current financial liabilities 703.5 834.2
Deferred tax liabilities 51.7 52.7
Other non-current liabilities 194.4 227.3
Total non-current liabilities 1,014.0 1,161.0
Current provisions 45.3 27.4
Current financial liabilities 272.4 142.8
Trade payables 1,016.1 854.2
Current tax liabilities 53.4 14.3
Other current liabilities 339.5 397.2
Bank overdrafts 8.5 4.0
Total current liabilities 1,735.2 1,439.9
TOTAL EQUITY & LIABILITIES 7,460.3 6,937.8
Press release
15
Appendix 3.1: consolidated statement of cash flow
H1 2026 H1 2025
€m €m
Consolidated net profit 402.6 335.5
Share of profit/(loss) from equity-accounted companies — 0.5
Net profit/(loss) before share from equity-accounted companies 402.6 336.1
Non-cash and non-operating items:
- Depreciation, amortization and provisions 290.8 195.8
- Change in fair value of financial derivatives 4.8 (19.3)
- Net gains or losses on disposals of non-current assets 1.8 (0.6)
- Net financing costs 3.3 4.2
- Income tax 143.9 102.1
- Share-based payment expense 21.2 17.6
- Other non-cash items (6.1) 23.2
Cash flow from operating activities before changes in working capital
requirements
862.3 658.9
- (Increase)/decrease in inventories 12.7 19.2
- (Increase)/decrease in trade receivables (173.1) (85.1)
- Increase/(decrease) in trade payables 153.6 43.2
- Net change in other operating assets and liabilities (37.3) (9.9)
Change in working capital requirements related to operating activities (44.2) (32.6)
Tax paid (125.1) (99.6)
NET CASH PROVIDED/(USED) BY OPERATING ACTIVITIES 693.1 526.7
Acquisition of property, plant & equipment (28.4) (55.3)
Acquisition of intangible assets (26.9) (118.6)
Proceeds from disposal of intangible assets and property, plant &
equipment
0.2 0.1
Acquisition and proceeds from disposal of shares in non-consolidated
companies
43.2 (1.3)
Change in working capital related to investment activities (57.6) 30.6
Other cash flow related to investment activities (5.6) 11.7
NET CASH PROVIDED/(USED) BY INVESTMENT ACTIVITIES (75.2) (132.9)
Additional long-term borrowings 5.9 499.5
Repayment of long-term borrowings (0.7) (1.0)
Additional short-term borrowings 0.4 —
Repayment of short-term borrowings (14.9) (17.0)
Treasury shares (17.3) (10.7)
Distributions paid by Ipsen S.A. (131.8) (116.2)
Interest paid (13.0) 0.2
NET CASH PROVIDED/(USED) BY FINANCING ACTIVITIES (171.4) 354.7
OPENING CASH AND CASH EQUIVALENTS 1,521.5 677.6
CHANGE IN CASH AND CASH EQUIVALENTS 446.5 748.5
Impact of exchange rate fluctuations (6.3) 16.8
CLOSING CASH AND CASH EQUIVALENTS 1,961.8 1,442.9
Press release
16
Appendix 3.2: consolidated net cash flow statement
H1 2026 H1 2025
€m €m
Opening Net cash /(Debt) 559.9 160.3
CORE OPERATING INCOME 844.9 655.8
Depreciation & Amortization 45.6 43.4
EBITDA 890.4 699.2
Non-cash items 22.1 17.6
(Increase) /decrease in inventories 12.7 6.3
(Increase) / decrease in trade receivables (173.1) (85.1)
Increase / (decrease) in trade payables 153.6 43.2
Change in operating working capital requirements (6.9) (35.6)
Other changes in working capital requirements (27.9) 4.5
Acquisition of property, plant & equipment (28.4) (55.3)
Acquisition of intangible assets (excluding milestones paid) (13.1) (11.0)
Disposal of fixed assets 0.2 0.1
Change in working capital related to investment activities (1.4) 2.4
Net capital expenditures (excluding milestones paid) (42.7) (63.9)
Operating Cash Flow 835.0 621.8
Other non-core operating income and expenses and restructuring costs (40.8) (22.2)
Financial income (17.4) (16.8)
Tax paid (125.1) (99.6)
Free Cash Flow 651.7 483.2
Distributions paid (including payout to non-controlling interests) (131.8) (116.2)
Acquisition and proceeds from disposal of shares in non-consolidated
companies
43.2 (1.3)
Impact of changes in consolidation scope — 10.2
Milestones paid (32.9) (90.0)
Other Business Development operations (50.3) 1.1
Net investments (Business Development and milestones) (40.1) (80.0)
Share buyback (17.3) (10.7)
FX on net indebtedness (12.0) 44.4
Other
(5.6) 6.5
Shareholders return and external growth operations
(206.8) (155.9)
Change in Net cash/(Debt) 445.0 327.3
Closing Net cash/(Debt)
1,004.9 487.6
Press release
17
Appendix 4: bridges from IFRS consolidated net profit to core consolidated net profit
The reconciliation items between core consolidated net profit and IFRS consolidated net profit are
described in the paragraph ‘From core financial measures to IFRS reported figures’.
IFRS
CORE
H1 2026
Amortization of
intangible assets
(excl software)
Other
operating
income or
expenses
Restructuring
Impairment
losses
Other H1 2026
€m €m €m €m €m €m €m
Sales 2,190.2 — — — — — 2,190.2
Other revenues 109.0 — — — — — 109.0
Cost of sales (435.2) — — — — — (435.2)
Gross Margin 1,864.0 — — — — — 1,864.0
Selling general and
administrative expenses
(607.7) — — — — — (607.7)
Research and development
expenses
(402.5) — — — — — (402.5)
Other core income and
expenses
(198.2) 122.8 66.4 — — — (9.0)
Restructuring costs (5.6) — — 5.6 — — —
Impairment losses (85.2) — — — 85.2 — —
Operating Income 564.8 122.8 66.4 5.6 85.2 — 844.9
Net financing costs (3.3) — — — — — (3.3)
Other financial income and
expenses
(13.8) — — — — (2.2) (16.0)
Income taxes (145.1) (30.7) (25.3) (1.5) (21.6) 6.3 (217.9)
Consolidated Net Profit 402.6 92.1 41.1 4.1 63.6 4.2 607.7
– Attributable to shareholders
of Ipsen S.A.
403.1 92.1 41.1 4.1 63.6 4.2 608.2
– Attributable to non-
controlling interests
(0.5) — — — — — (0.5)
Earnings Per Share Fully Diluted
– attributable to Ipsen S.A.
shareholders (in € per share)
€ 4.86 € 1.11 € 0.50 € 0.05 € 0.77 € 0.05 € 7.33
Press release
18
IFRS
CORE
H1 2025
Amortization of
intangible assets
(excl software)
Other
operating
income or
expenses
Restructuring
Impairment
losses
Other H1 2025
€m €m €m €m €m €m €m
Sales 1,819.8 — — — — — 1,819.8
Other revenues 117.3 — — — — — 117.3
Cost of sales (371.0) — — — — — (371.0)
Gross Margin 1,566.1 — — — — — 1,566.1
Selling general and
administrative expenses
(560.7) — — — — — (560.7)
Research and development
expenses
(364.9) — — — — — (364.9)
Other operating income and
expenses
(133.1) 132.2 16.2 — — — 15.3
Restructuring costs (2.8) — — 2.8 — — —
Impairment losses (53.0) — — — 53.0 — —
Operating Income 451.6 132.2 16.2 2.8 53.0 — 655.8
Net financing costs (4.2) — — — — — (4.2)
Other financial income and
expenses
(21.9) — — — — 15.5 (6.5)
Income taxes (89.5) (33.1) (3.9) (0.8) (13.7) 4.1 (136.9)
Share of profit/(loss) from
equity-accounted companies
(0.5) — — — — 0.5 —
Consolidated Net Profit 335.5 99.1 12.2 2.0 39.3 20.1 508.3
– Attributable to shareholders
of Ipsen S.A.
334.0 99.1 12.2 2.0 39.3 20.1 506.8
– Attributable to non-
controlling interests
1.5 — — — — — 1.5
Earnings Per Share Fully Diluted
– attributable to Ipsen S.A.
shareholders (in € per share)
€ 4.00 € 1.19 € 0.15 € 0.02 € 0.47 € 0.24 € 6.07
Press release
19
Appendix: half-year geographic breakdown of total sales by medicine
Total
North America
Europe
Rest of World
H1 2026 H1 2025 % change
H1 2026 H1 2025 % change
H1 2026 H1 2025 % change
H1 2026 H1 2025 % change
€m €m Actual CER
€m €m Actual CER
€m €m Actual CER
€m €m Actual CER
Oncology 1,451.5 1,288.0 12.7 % 15.6 %
484.8 424.9 14.1 % 21.7 %
628.0 576.5 8.9 % 9.1 %
338.7 286.7 18.2 % 19.9 %
Somatuline
®
686.3 588.6 16.6 % 21.0 %
380.1 309.1 22.9 % 31.1 %
214.4 196.9 8.9 % 9.2 %
91.8 82.5 11.3 % 12.1 %
Cabometyx
®
350.5 296.7 18.1 % 18.8 %
10.7 9.5 12.3 % 17.3 %
242.7 211.3 14.9 % 14.9 %
97.1 75.9 27.9 % 29.9 %
Decapeptyl
®
284.3 277.1 2.6 % 3.5 %
— — — —
145.6 150.9 -3.5 % -3.3 %
138.7 126.3 9.8 % 11.8 %
Onivyde
®
108.0 102.7 5.2 % 11.2 %
87.8 86.6 1.3 % 8.2 %
19.4 15.2 27.6 % 28.1 %
0.9 0.9 -0.6 % -0.1 %
Ojemda
®
14.5 0.9 n/a n/a
— — — —
4.3 0.7 n/a n/a
10.2 0.2 n/a n/a
Other Oncology 7.9 22.0 -63.9 % -61.8 %
6.3 19.6 -68.0 % -65.8 %
1.6 1.5 4.1 % 4.2 %
0.1 0.9 n/a n/a
Rare Disease 304.7 153.4 98.6 % 108.0 %
209.3 103.6 102.1 % 115.8 %
77.6 42.9 80.8 % 80.8 %
17.8 6.9 157.8 % 165.5 %
Iqirvo
®
173.2 58.8 194.6 % 209.7 %
130.1 45.2 187.7 % 207.2 %
40.3 13.3 202.1 % 202.6 %
2.8 0.2 n/a n/a
Bylvay® 120.1 86.6 38.6 % 44.8 %
71.3 52.9 34.6 % 43.8 %
36.4 28.8 26.1 % 26.0 %
12.4 4.8 156.7 % 172.4 %
Other Rare Disease 11.4 8.0 42.7 % 47.2 %
7.9 5.4 46.2 % 56.1 %
0.9 0.8 25.6 % 25.6 %
2.5 1.8 39.3 % 30.7 %
Neuroscience 434.0 378.4 14.7 % 16.6 %
101.3 106.5 -4.8 % 3.2 %
118.4 102.5 15.5 % 14.9 %
214.2 169.4 26.4 % 25.8 %
Dysport
®
427.1 371.0 15.1 % 17.2 %
101.3 106.5 -4.8 % 3.2 %
118.4 102.5 15.5 % 14.9 %
207.3 162.0 28.0 % 27.6 %
Dysport Aesthetics 256.8 221.4 16.0 % 19.6 %
69.7 76.4 -8.8 % -0.5 %
29.2 25.3 15.4 % 14.4 %
158.0 119.7 32.0 % 33.0 %
Dysport Therapeutics 170.2 149.5 13.8 % 13.8 %
31.6 30.0 5.3 % 12.4 %
89.2 77.2 15.6 % 15.0 %
49.4 42.3 16.7 % 12.5 %
Other Neuroscience 6.9 7.5 -7.1 % -12.9 %
— — — —
— — — —
6.9 7.5 -7.1 % -12.9 %
Total Sales 2,190.2 1,819.8 20.4 % 23.5 %
795.4 634.9 25.3 % 34.0 %
824.1 721.9 14.1 % 14.2 %
570.7 463.0 23.3 % 24.2 %
Press release
20
Appendix: Q2 geographic breakdown of total sales by medicine
Total
North America
Europe
Rest of World
Q2 2026 Q2 2025 % change
Q2 2026 Q2 2025 % change
Q2 2026 Q2 2025 % change
Q2
2026
Q2
2025
% change
€m €m Actual CER
€m €m Actual CER
€m €m Actual CER
€m €m Actual CER
Oncology 744.0 633.0 17.5 % 18.2 %
251.5 196.1 28.3 % 30.9 %
317.6 290.4 9.4 % 9.5 %
174.8 146.5 19.3 % 18.3 %
Somatuline
®
357.5 278.2 28.5 % 29.7 %
201.9 137.8 46.5 % 49.1 %
106.8 98.8 8.1 % 8.3 %
48.8 41.5 17.6 % 15.6 %
Cabometyx
®
181.4 149.9 21.1 % 21.1 %
5.5 4.6 17.6 % 20.5 %
123.6 108.5 13.9 % 13.9 %
52.4 36.7 42.8 % 42.6 %
Decapeptyl
®
140.2 141.3 -0.8 % -1.1 %
— — — —
72.7 74.9 -2.9 % -2.8 %
67.5 66.3 1.7 % 0.8 %
Onivyde
®
54.9 51.0 7.7 % 10.0 %
44.2 43.1 2.5 % 5.2 %
9.9 7.0 40.8 % 41.3 %
0.9 0.9 -0.6 % -0.1 %
Ojemda
®
9.2 0.5 n/a n/a
— — — —
4.0 0.4 n/a n/a
5.2 0.2 n/a n/a
Other Oncology 0.7 12.1 -93.9 % -94.1 %
— 10.6 — —
0.7 0.8 -7.4 % -7.3 %
— 0.8 — —
Rare Disease 157.6 83.1 89.7 % 94.0 %
111.1 56.5 96.5 % 102.9 %
38.9 23.0 69.0 % 68.9 %
7.7 3.6 116.6 % 114.6 %
Iqirvo
®
94.4 35.5 165.9 % 174.1 %
72.5 27.5 163.6 % 174.1 %
20.1 7.8 158.0 % 158.3 %
1.8 0.2 n/a n/a
Bylvay
®
58.9 43.2 36.3 % 38.4 %
35.2 26.2 34.2 % 37.6 %
18.3 14.9 23.2 % 23.0 %
5.4 2.1 153.4 % 154.0 %
Other Rare Disease 4.3 4.4 -1.4 % -0.8 %
3.4 2.8 20.2 % 23.5 %
0.4 0.3 26.0 % 26.0 %
0.5 1.2 -58.8 % -65.0 %
Neuroscience 213.7 184.9 15.6 % 14.7 %
41.9 48.0 -12.8 % -8.9 %
60.1 51.1 17.5 % 16.7 %
111.8 85.8 30.3 % 26.5 %
Dysport
®
210.1 180.7 16.3 % 15.5 %
41.9 48.0 -12.8 % -8.9 %
60.1 51.1 17.5 % 16.7 %
108.2 81.5 32.7 % 28.9 %
Dysport Aesthetics 119.5 104.3 14.5 % 14.6 %
25.0 32.3 -22.4 % -18.2 %
13.7 11.2 22.0 % 20.5 %
80.7 60.8 32.7 % 30.4 %
Dysport Therapeutics 90.6 76.3 18.7 % 16.9 %
16.8 15.8 6.7 % 9.9 %
46.4 39.9 16.2 % 15.7 %
27.4 20.7 32.7 % 24.5 %
Other Neuroscience
3.6 4.2 -14.8 % -20.1 %
— — — —
— — — —
3.6 4.2 -14.8 % -20.1 %
Total Sales 1,115.3 901.0 23.8 % 24.5 %
404.5 300.7 34.5 % 38.1 %
416.5 364.5 14.3 % 14.3 %
294.3 235.8 24.8 % 22.7 %
Press release
21
Disclaimers and/or forward-looking statements
The forward-looking statements, objectives and targets contained herein are based on Ipsen’s
management strategy, current views and assumptions. Such statements involve known and unknown risks
and uncertainties that may cause actual results, performance or events to differ materially from those
anticipated herein. All of the above risks could affect Ipsen’s future ability to achieve its financial targets,
which were set assuming reasonable macroeconomic conditions based on the information available
today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to
identify forward-looking statements, including Ipsen’s expectations regarding future events, including
regulatory filings and determinations. Moreover, the targets described in this document were prepared
without taking into account external-growth assumptions and potential future acquisitions, which may
alter these parameters. These objectives are based on data and assumptions regarded as reasonable by
Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on
historical data. Actual results may depart significantly from these targets given the occurrence of certain
risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical
trial may end up never being launched on the market or reaching its commercial targets, notably for
regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that
might translate into a loss of market share. Furthermore, the research and development process involves
several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and
be forced to abandon its efforts with regards to a medicine in which it has invested significant sums.
Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be
confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to
demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a
medicine will receive the necessary regulatory approvals or that the medicine will prove to be
commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize,
actual results may differ materially from those set forth in the forward-looking statements. Other risks
and uncertainties include but are not limited to, general industry conditions and competition; general
economic factors, including interest rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and healthcare legislation and risks arising from unexpected
regulatory or political changes such as changes in tax regulation and regulations on trade and tariffs, such
as protectionist measures, especially in the United States; global trends toward healthcare cost
containment; technological advances, new medicine and patents attained by competitors; challenges
inherent in new-medicine development, including obtaining regulatory approval; Ipsen’s ability to
accurately predict future market conditions; manufacturing difficulties or delays; financial instability of
international economies and sovereign risk; dependence on the effectiveness of Ipsen’s patents and
other protections for innovative medicines; and the exposure to litigation, including patent litigation,
and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its
medicines which could potentially generate substantial royalties; these partners could behave in such
ways which could cause damage to Ipsen’s activities and financial results. Ipsen cannot be certain that
its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A
default by any of Ipsen’s partners could generate lower revenues than expected. Such situations could
have a negative impact on Ipsen’s business, financial position or performance. Ipsen expressly disclaims
any obligation or undertaking to update or revise any forward-looking statements, targets or estimates
contained in this press release to reflect any change in events, conditions, assumptions or circumstances
on which any such statements are based, unless so required by applicable law. Ipsen’s business is subject
to the risk factors outlined in its registration documents filed with the French Autorité des Marchés
Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to
Ipsen’s latest Universal Registration Document, available on ipsen.com.